TY  - BOOK
AU  - Sahay,Manisha
AU  - Jasuja,Sanjiv
AU  - Tang,Sydney Chi Wai
AU  - Alexander,Suceena
AU  - Jha,Vivekanand
AU  - Vachharajani,Tushar
AU  - Mostafi,Mamun
AU  - Pisharam,Jayakrishnan K
AU  - Jacob,Chakko
AU  - Gunawan,Atma
AU  - Leong,Goh Bak
AU  - Thwin,Khin Thida
AU  - Agrawal,Rajendra Kumar
AU  - Vareesangthip,Kriengsak
AU  - Tanchanco,Roberto
AU  - Choong,Lina
AU  - Herath,Chula
AU  - Lin,Chih-Ching
AU  - Cuong,Nguyen The
AU  - Haian,Ha Phan
AU  - Akhtar,Syed Fazal
AU  - Alsahow,Ali
AU  - Rana,Devinder S
AU  - Rajapurkar,Mohan M
AU  - Kher,Vijay
AU  - Verma,Shalini
AU  - Ramachandran,Raja
AU  - Bhargava,Vinant
AU  - Puri,Sonika
AU  - Sagar,Gaurav
AU  - Bahl,Anupam
AU  - Mandal,Sandeep
AU  - Gupta,Ashwani
AU  - Gallieni,Maurizio
TI  - Aetiology, practice patterns and burden of end-stage kidney disease in South Asia and South-East Asia: a questionnaire-based survey 
KW  - Kidney Failure, Chronic
KW  - Renal Replacement Therapy
KW  - Cost of Illness
KW  - Burden Of Disease
N2  - Aim: There is paucity of data on the epidemiology of end-stage kidney disease (ESKD) from South Asia and South-East Asia. The objective of this study was to assess the aetiology, practice patterns and disease burden and growth of ESKD in the region comparing the economies.

Methods: The national nephrology societies of the region; responded to the questionnaire; based on latest registries, acceptable community-based studies and society perceptions. The countries in the region were classified into Group 1 (High|higher-middle-income) and Group 2 (lower|lowermiddle income). Student t-test, Mann-Whitney U test and Fisher's exact test were used for comparison.

Results: Fifteen countries provided the data. The average incidence of ESKD was estimated at 226.7 per million population (pmp), (Group 1 vs. Group 2, 305.8 vs. 167.8 pmp) and average prevalence at 940.8 pmp (Group 1 vs. Group 2, 1306 vs. 321 pmp). Group 1 countries had a higher incidence and prevalence of ESKD. Diabetes, hypertension and chronic glomerulonephritis were most common causes. The mean age in Group 2 was lower by a decade (Group 1 vs. Group 2-59.45 vs 47.7 years).

Conclusion: Haemodialysis was the most common kidney replacement therapy in both groups and conservative management of ESKD was the second commonest available treatment option within Group 2. The disease burden was expected to grow >20% in 50% of Group 1 countries and 78% of Group 2 countries along with the parallel growth in haemodialysis and peritoneal dialysis
ER  -